We rank companies based on fund manager, research analyst and news sentiment
HALO stock icon

Halozyme
HALO

$38.64
2.2%
 

About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Employees: 373

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 11 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

133% more call options, than puts

Call options by funds: $10.2M | Put options by funds: $4.39M

35% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 46

4% more funds holding

Funds holding: 382 [Q3] → 398 (+16) [Q4]

1.6% more ownership

Funds ownership: 92.03% [Q3] → 93.63% (+1.6%) [Q4]

1% less repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 142

1% less capital invested

Capital invested by funds: $4.64B [Q3] → $4.58B (-$62.1M) [Q4]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 2 (-3) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$40
4%
upside
Avg. target
$54
40%
upside
High target
$72
86%
upside

11 analyst ratings

10 positive
91%
neutral
9%
negative
0%
HC Wainwright & Co.
Mitchell Kapoor
29%upside
$50
Buy
Reiterated
17 Apr 2024
Benchmark
Robert Wasserman
29%upside
$50
Buy
Reiterated
16 Apr 2024
TD Cowen
Brendan Smith
40%upside
$54
Outperform
Initiated
29 Feb 2024
JMP Securities
Jason Butler
86%upside
$72
Market Outperform
Reiterated
21 Feb 2024
HC Wainwright & Co.
Mitchell Kapoor
29%upside
$50
Buy
Maintained
21 Feb 2024

Financial journalist opinion

Based on 5 articles about HALO published over the past 30 days